Global Metastatic Bone Pain Market

Description

Overview

Global Metastatic Bone Pain Market reached US$ 14.4 billion in 2023 and is expected to reach US$ 24 billion by 2031, growing at a CAGR of 6.7% during the forecast period 2024-2031.

Pain is the most common symptom of bone metastases. It tends to be a constant, aching pain that may be worse during activity and can cause sleeping difficulties. Bone pain from cancer tends to be quite different from the pain caused by common conditions such as arthritis or muscular strains.

Market Dynamics: Drivers & Restraints

Rise in the prevalence of cancers

As cancer prevalence increases globally, so does the incidence of bone metastases. Cancers such as breast, prostate, and lung frequently metastasize to bones, leading to a growing need for effective pain management solutions. For instance, according to the American Cancer Society in 2023, the US experienced 1,958,310 new cancer cases and 609,820 deaths, as per the data from central cancer registries and the National Center for Health Statistics, based on population-based cancer occurrence and outcomes.

Complications associated with the drugs

Metastatic bone pain treatments like opioids and radiation therapy have significant side effects, including addiction, tolerance, and health complications. Radiation therapy can cause skin reactions, fatigue, and systemic effects. Surgical interventions, while beneficial in some cases, carry risks of infections, blood loss, and long recovery times.

Market Segment Analysis

The global metastatic bone pain market is segmented based on drug type, route of administration, end-user, and region.

The NSAIDs from the drug type segment accounted for approximately 47.3%. of the metastatic bone pain market share

The NSAIDs from the drug type segment accounted for approximately 47.3%. Non-steroidal anti-inflammatory drugs have been in use for the treatment of pain control for all diseases. They also have an anti-inflammatory effect that makes them an ideal drug for the inflammation caused by certain cancer types during extensive tissue invasion and destruction. A Cochrane review by McNicol and colleagues found that NSAIDs appear to be more effective than placebo for cancer pain.

Market Geographical Share

North America is estimated to hold about 38.4% of the total market share throughout the forecast period

North America is estimated to hold about 38.4% of the total market share throughout the forecast period owing to factors like novel product launches, ongoing clinical trials, FDA approvals, advanced healthcare infrastructure in the region, collaborations and partnerships, and others that help the region to grow during the forecast period.

For instance, in May 2024, the American Society for Radiation Oncology (ASTRO) outlined recommendations on best practices for treating patients with symptomatic bone metastases and strategies to improve their quality of life, according to updated clinical guidelines published by Alcorn et al in Practical Radiation Oncology.

Radiation therapy was strongly recommended to manage pain and other symptoms of bone or spine metastases, including those causing compression of the spinal cord or cauda equina.

Surgery and dexamethasone combined with radiation therapy were recommended over radiation therapy alone in patients with spine metastases causing spinal cord or cauda equina compression. Postoperative radiation therapy was recommended in patients with non-spine bone metastases requiring surgery.

Market Segmentation

By Drug Type

Non-steroidal Anti-inflammatory Drugs

Opioids

Bisphosphonates

Corticosteroids

Others

By Route of Administration

Oral

Injectable

Transdermal

By End User

Hospitals

Specialty Clinics

Home Care Settings

Ambulatory Surgical Centers

Others

By Region

North America

The U.S.

Canada

Mexico

Europe

Germany

France

Italy

Spain

Rest of Europe

South America

Brazil

Argentina

Rest of South America

Asia-Pacific

China

India

Japan

South Korea

Rest of Asia-Pacific

Middle East and Africa

Market Competitive Landscape

The major global players in the market include Amgen Inc., Novartis AG, Bayer AG, Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Fresenius Kabi, Stryker Corporation, Medtronic plc, Eli Lilly and Company among others.

Why Purchase the Report?

To visualize the global metastatic bone pain market segmentation based on drug type, route of administration, end-user, and region as well as understand key commercial assets and players.

Identify commercial opportunities by analyzing trends and co-development.

Excel data sheet with numerous data points of the metastatic bone pain market level with all segments.

PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.

Product mapping available as Excel consisting of key products of all the major players.

The global metastatic bone pain market report would provide approximately 64 tables, 61 figures, and 186 pages.

Target Audience 2024

Manufacturers/ Buyers

Industry Investors/Investment Bankers

Research Professionals

Emerging Companies

Product Code: PH8559

1. Methodology and Scope

1.1. Research Methodology
1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

3.1. Snippet by Drug Type
3.2. Snippet by Route of Administration
3.3. Snippet by End User
3.4. Snippet by Region

4. Dynamics

4.1. Impacting Factors
- 4.1.1. Drivers
  - 4.1.1.1. Rise in the prevalence of Cancers
  - 4.1.1.2. Rise of advancements in treatment options
- 4.1.2. Restraints
  - 4.1.2.1. Complications associated with the drugs
- 4.1.3. Opportunity
- 4.1.4. Impact Analysis

5. Industry Analysis

5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. Patent Analysis
5.6. PESTLE Analysis
5.7. SWOT Analysis
5.8. DMI Opinion

6. By Drug Type

6.1. Introduction
- 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
- 6.1.2. Market Attractiveness Index, By Drug Type
6.2. Non-steroidal Anti-inflammatory Drugs*
- 6.2.1. Introduction
6.3. Opioids
6.4. Bisphosphonates
6.5. Corticosteroids
6.6. Others

7. By Route of Administration

7.1. Introduction
- 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
- 7.1.2. Market Attractiveness Index, By Route of Administration
7.2. Oral*
- 7.2.1. Introduction
7.3. Injectable
7.4. Transdermal

8. By End User

8.1. Introduction
- 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 8.1.2. Market Attractiveness Index, By End User
8.2. Hospitals*
- 8.2.1. Introduction
- 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Specialty Clinics
8.4. Home Care Settings
8.5. Ambulatory Surgical Centers
8.6. Others

9. By Region

9.1. Introduction
- 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
- 9.1.2. Market Attractiveness Index, By Region
9.2. North America
- 9.2.1. Introduction
- 9.2.2. Key Region-Specific Dynamics
- 9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
- 9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
- 9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 9.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 9.2.6.1. The U.S.
  - 9.2.6.2. Canada
  - 9.2.6.3. Mexico
9.3. Europe
- 9.3.1. Introduction
- 9.3.2. Key Region-Specific Dynamics
- 9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
- 9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
- 9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 9.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 9.3.6.1. Germany
  - 9.3.6.2. UK
  - 9.3.6.3. France
  - 9.3.6.4. Italy
  - 9.3.6.5. Spain
  - 9.3.6.6. Rest of Europe
9.4. South America
- 9.4.1. Introduction
- 9.4.2. Key Region-Specific Dynamics
- 9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
- 9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
- 9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 9.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 9.4.6.1. Brazil
  - 9.4.6.2. Argentina
  - 9.4.6.3. Rest of South America
9.5. Asia-Pacific
- 9.5.1. Introduction
- 9.5.2. Key Region-Specific Dynamics
- 9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
- 9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
- 9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 9.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 9.5.6.1. China
  - 9.5.6.2. India
  - 9.5.6.3. Japan
  - 9.5.6.4. South Korea
  - 9.5.6.5. Rest of Asia-Pacific
9.6. Middle East and Africa
- 9.6.1. Introduction
- 9.6.2. Key Region-Specific Dynamics
- 9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
- 9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
- 9.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User

10. Competitive Landscape

10.1. Competitive Scenario
10.2. Market Positioning/Share Analysis
10.3. Mergers and Acquisitions Analysis

11. Company Profiles

11.1. Amgen Inc *
- 11.1.1. Company Overview
- 11.1.2. Product Portfolio and Description
- 11.1.3. Financial Overview
- 11.1.4. Key Developments
11.2. Novartis AG
11.3. Bayer AG
11.4. Pfizer Inc
11.5. Merck & Co. Inc
11.6. AbbVie Inc
11.7. Fresenius Kabi
11.8. Stryker Corporation
11.9. Medtronic plc
11.10. Eli Lilly and Company (*LIST NOT EXHAUSTIVE)

12. Appendix

12.1. About Us and Services
12.2. Contact Us

Global Metastatic Bone Pain Market - 2024-2031